Overweight and glucose/lipid metabolism abnormality associated with SSRIs: a pharmacovigilance study based on the FDA adverse event reporting system
Our study screened for adverse effects associated with abnormal glucose/lipid metabolism, such as abnormal body weight and fatty liver, in depressed patients taking selective serotonin reuptake inhibitors by utilizing FAERS database. This provides valuable insights for healthcare professionals in accepting and managing patients treated with SSRIs.
Authors
- Zhijun Xiao (ORCID: https://orcid.org/0000-0001-6396-6820)
- Yunpeng Ma
- Zhen Yang (ORCID: https://orcid.org/0000-0001-9763-6766)
- Yan Wang (ORCID: https://orcid.org/0000-0002-8031-0716)
- Jian Cai (ORCID: https://orcid.org/0000-0003-3756-219X)
- Xu Feng (ORCID: https://orcid.org/0000-0003-1091-479X)
- Zhicong Chen (ORCID: https://orcid.org/0000-0002-7549-4696)
- Jinming Cao (ORCID: https://orcid.org/0000-0002-8614-7366)
Institutions
- Xian Mental Health Center (CN)
- Shanghai Sixth People's Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-01-10
- DOI
- https://doi.org/10.3389/fphar.2024.1517546
- Citations
- 3
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 3.92